Date: 2011-06-29
Type of information: Fundraising
Company: Prosonix (UK)
Investors: Ventech (France) - Gilde Healthcare Partners (Netherlands) - Entrepreneurs Fund (UK) - Quest for Growth (Belgium)
Solon Ventures (UK)
Amount: £11.4 million
Funding type: series B financing round
Planned used: The proceeds of the financing will be used to progress the Company’s emerging proprietary product pipeline of mono and multi-component combination therapies, and through Phase 2 Clinical trials as required. Prosonix patented particle engineering technology provides a unique opportunity to develop novel and generic mono and combination respiratory medicines efficiently in a range of affordable and commercially available Metered Dose and Dry Powder Inhalers.
Others: Prosonix, a company specialized in the development of high value respiratory therapies enabled by its novel and proprietary particle engineering technology, has announced the successful conclusion of a £11.4M financing round. The round was led by Ventech (France), with support from additional new Investor Gilde Healthcare Partners (Netherlands) and existing Investors including Entrepreneurs Fund (UK), Quest for Growth (Belgium) and Solon Ventures (UK).
Therapeutic area: Respiratory diseases
